Comparing the current results to its competitors, Galectin Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 92.42 %, recorded in the same quarter.
Galectin Therapeutics Inc 's Comment on Competition and Industry Peers
The company’s competitive position relies on developing and maintaining proprietary technology while avoiding infringement on others’ intellectual property rights. It protects its intellectual property through patents, trademarks, trade secrets, copyrights, confidentiality agreements, and restricted access. The company focuses on designing and testing agents that target galectins for the treatment of fibrosis and the enhancement of immune responsiveness, utilizing independent laboratories for research activities.
December 20, 2024
Navigating New Frontiers: Galectin Therapeutics Shares Promising Results from NAVIGATE Trial Amid Industry Challenges In an era marked by rapid advancements in biotechnology, Galectin Therapeutics, Inc. (NASDAQ: GALT) stands at the helm of innovation, recently unveiling top-line results from its global NAVIGATE clinical trial. This groundbreaking study evaluates the efficacy of belapectin in treating patients suffering from Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension a condition that silently spreads in the shadows of metabolic disorders affecting liver health.On December 20, 2024, the Norcross, Georgia-based company presented outcomes that could reshape the para...
Publicly Traded Peers of Galectin Therapeutics Inc
Crescent Biopharma Inc Share Performance
+17.63%
Over The Past 5 Days
Crescent Biopharma Inc
Profile
The company is a clinical-stage biotechnology firm focused on developing PD-1 x VEGF bispecific antibodies and antibody-drug conjugates for cancer treatment.
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.
Rapt Therapeutics Inc operates based on a business model that focuses on developing and commercializing transformative oral small molecules, known as immunomodulators. Their compounds target specific immune cell subsets within the body to provide potential therapeutic benefits in various diseases. By leveraging their expertise in immunology and small molecule drug design, Rapt strives to deliver innovative treatment options to patients in need.
Oncotelic Therapeutics Inc is a biotechnology company that focuses on developing and commercializing novel therapeutics for the treatment of cancer. Their business model revolves around conducting research to develop innovative drugs and therapies, and subsequently bringing those products to market to generate revenue and improve patient outcomes in cancer treatment.
Sources:
Galectin Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Galectin Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
